Lion Biotechnologies to Present at Cowen and Company's 35th Annual Healthcare Conference
03 March 2015 - 12:30AM
Lion Biotechnologies, Inc. (Nasdaq:LBIO) announced that president
and CEO Elma Hawkins, PhD, will present at Cowen and Company's 35th
Annual Healthcare Conference on Wednesday, March 4, 2015. Dr.
Hawkins will present at 8:40 a.m. EST.
A webcast of Dr. Hawkins' presentation will be available both
live and on replay. The presentation will be available via webcast
at http://wsw.com/webcast/cowen22/lbio. The live webcast and
subsequent archived replay of Lion Biotechnologies' presentation
will also be accessible via the Investors section of the Company's
web site at http://lbio.com/investors/ under "Recent Events."
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of T
cells and engineered T cells for the treatment of various cancers.
The company's lead product candidate, LN-144, is a ready-to-infuse,
autologous T-cell therapy utilizing tumor-infiltrating lymphocytes
(TIL) for the treatment of patients with metastatic melanoma, and
is based on a clinical Cooperative Research and Development
Agreement with the National Cancer Institute. TIL therapy is also
being evaluated in physician-sponsored clinical trials at MD
Anderson Cancer Center and the H. Lee Moffitt Cancer Center &
Research Institute. For more information, please visit
http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements
that are subject to a number of risks and uncertainties, including
the risks relating to the Company's ability to conduct its Phase 2
clinical trial in metastatic melanoma and to further successfully
develop or commercialize the Company's TIL technologies. Additional
risks and uncertainties are described in the Company's most
recently filed quarterly report on Form 10-Q and annual report on
Form 10-K. Except as permitted by law, the Company undertakes no
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT: Investor Relations
The Trout Group
Tricia Truehart
646-378-2953
ttruehart@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2024 to May 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From May 2023 to May 2024